ZA200502618B - Human papillomavirus polypeptides and immunogenic compositions - Google Patents

Human papillomavirus polypeptides and immunogenic compositions

Info

Publication number
ZA200502618B
ZA200502618B ZA200502618A ZA200502618A ZA200502618B ZA 200502618 B ZA200502618 B ZA 200502618B ZA 200502618 A ZA200502618 A ZA 200502618A ZA 200502618 A ZA200502618 A ZA 200502618A ZA 200502618 B ZA200502618 B ZA 200502618B
Authority
ZA
South Africa
Prior art keywords
immunogenic compositions
human papillomavirus
papillomavirus polypeptides
polypeptides
human
Prior art date
Application number
ZA200502618A
Other languages
English (en)
Inventor
Smith Larry
Susan P Mcelhiney
Cassetti Maria Christina
Jeffrey K Pullen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200502618B publication Critical patent/ZA200502618B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ZA200502618A 2002-10-03 2005-03-31 Human papillomavirus polypeptides and immunogenic compositions ZA200502618B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41592902P 2002-10-03 2002-10-03

Publications (1)

Publication Number Publication Date
ZA200502618B true ZA200502618B (en) 2008-10-29

Family

ID=32069921

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200502618A ZA200502618B (en) 2002-10-03 2005-03-31 Human papillomavirus polypeptides and immunogenic compositions

Country Status (16)

Country Link
US (2) US7223408B2 (enExample)
EP (1) EP1553966B1 (enExample)
JP (2) JP4755422B2 (enExample)
KR (1) KR101145190B1 (enExample)
CN (1) CN1720060B (enExample)
AU (1) AU2003282731B2 (enExample)
BR (1) BR0314529A (enExample)
CA (1) CA2499837C (enExample)
CO (1) CO5700784A2 (enExample)
DK (1) DK1553966T3 (enExample)
ES (1) ES2391451T3 (enExample)
MX (1) MXPA05003395A (enExample)
NZ (1) NZ556544A (enExample)
PT (1) PT1553966E (enExample)
WO (1) WO2004030636A2 (enExample)
ZA (1) ZA200502618B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
WO2002012281A2 (en) 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
DK1553966T3 (da) * 2002-10-03 2012-09-17 Wyeth Corp Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US8399610B2 (en) * 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
JP4474264B2 (ja) 2004-08-20 2010-06-02 生寶生物科技股▲ふん▼有限公司 子宮頸癌抑制の融合蛋白
US7354719B2 (en) 2004-12-08 2008-04-08 Gen-Probe Incorporated Detection of nucleic acids from multiple types of human papillomaviruses
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
EP1838865A4 (en) * 2005-01-14 2008-09-03 Univ Michigan Systems, methods, and compositions for detection of human papilloma virus in biological samples
EP1846026A4 (en) * 2005-01-26 2008-07-02 Univ Johns Hopkins ANTIBODY DNA VACCINE WITH PLASMIDES FOR CODING A MUTATED ONCOPROTEIN ANTIGEN AND CALRETICULIN
JP5345053B2 (ja) * 2006-04-19 2013-11-20 浦項工科大學校 産學協力團 子宮頸癌の予防及び治療のためのヒトパピローマウイルスポリペプチドと免疫増強剤を含む組成物
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2722336A1 (en) * 2007-06-01 2014-04-23 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
US20120121715A1 (en) * 2008-01-02 2012-05-17 National Taiwan University DNA Vaccine Comprising IL-6-Encoding DNA Construct and Applications Thereof
EP2335730A1 (en) * 2009-12-18 2011-06-22 Deutsches Krebsforschungszentrum Fusion polypeptides and their use for prevention and treatment of cancer
KR101197627B1 (ko) 2010-01-18 2012-11-07 (주)레퍼런스바이오랩 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
CA2981303C (en) * 2010-02-16 2020-06-30 Becton, Dickinson And Company Assay for detecting closely-related serotypes of human papillomavirus (hpv)
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
EP2604629B1 (en) * 2010-08-13 2018-02-28 Genexine, Inc. Composition for preventing or treating cervical cancer having human papillomavirus immunity enhancer
KR102216962B1 (ko) * 2011-10-12 2021-02-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법
AU2012356969B2 (en) * 2011-12-21 2017-05-04 Nykode Therapeutics ASA Vaccines against HPV
EP2806889B1 (en) 2012-01-24 2017-08-16 Sanford Health Polynucleotides for treating oncogenic viral polypeptide positive tumors
CN103288931B (zh) * 2012-02-24 2015-05-27 宋硕 人类乳头瘤病毒免疫原性多肽、其制备方法及应用
US10232030B2 (en) * 2013-03-12 2019-03-19 Inovio Pharmaceuticals, Inc. Vaccines for human papilloma virus and methods for using the same
KR20250162628A (ko) * 2013-03-15 2025-11-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 암 백신 및 이를 이용한 치료 방법
WO2016024255A1 (en) * 2014-08-15 2016-02-18 Genexine, Inc. Methods of treating cervical cancer
JP5973007B2 (ja) * 2015-01-30 2016-08-17 ジェネクサイン・インコーポレーテッド ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
EP3875477A1 (en) * 2015-04-17 2021-09-08 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
CA2987155A1 (en) * 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
PL3359183T3 (pl) * 2015-10-06 2020-11-02 Invectys Konstrukty poliepitopowe do zastosowania w immunoterapii
US20190022202A1 (en) 2016-01-08 2019-01-24 Vaccibody As Therapeutic anticancer neoepitope vaccine
CA3019199A1 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
CN112574317B (zh) * 2017-01-24 2023-12-05 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
EP3461497A1 (en) * 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
WO2021026335A1 (en) * 2019-08-08 2021-02-11 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
IL297502A (en) 2020-04-24 2022-12-01 Genexine Inc A method for treating cervical cancer
CN114478712B (zh) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
WO2024145863A1 (en) * 2023-01-05 2024-07-11 Virogin Biotech (Shanghai) Ltd. A NOVEL mRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS
CN117925916A (zh) * 2024-03-11 2024-04-26 广州市金域转化医学研究院有限公司 Hpv dna的e6基因在制备浸润性宫颈癌诊断产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
WO2001077142A1 (en) * 2000-04-05 2001-10-18 Impact Diagnostics, Inc. Immunological methodology for discerning human papillomavirus
DK1553966T3 (da) * 2002-10-03 2012-09-17 Wyeth Corp Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf

Also Published As

Publication number Publication date
AU2003282731A1 (en) 2004-04-23
JP5398665B2 (ja) 2014-01-29
CN1720060A (zh) 2006-01-11
MXPA05003395A (es) 2005-06-22
ES2391451T3 (es) 2012-11-26
US7378099B2 (en) 2008-05-27
CO5700784A2 (es) 2006-11-30
WO2004030636A3 (en) 2005-02-24
JP4755422B2 (ja) 2011-08-24
EP1553966B1 (en) 2012-08-01
KR101145190B1 (ko) 2012-05-14
CA2499837A1 (en) 2004-04-15
CA2499837C (en) 2013-12-03
AU2003282731B2 (en) 2009-01-08
CN1720060B (zh) 2011-12-14
JP2010279386A (ja) 2010-12-16
WO2004030636A2 (en) 2004-04-15
KR20050053732A (ko) 2005-06-08
EP1553966A2 (en) 2005-07-20
BR0314529A (pt) 2005-08-09
EP1553966A4 (en) 2008-04-16
DK1553966T3 (da) 2012-09-17
US20070275003A1 (en) 2007-11-29
JP2006501825A (ja) 2006-01-19
PT1553966E (pt) 2012-10-22
US7223408B2 (en) 2007-05-29
NZ556544A (en) 2008-11-28
US20060014926A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
ZA200502618B (en) Human papillomavirus polypeptides and immunogenic compositions
EP1551376A4 (en) IMMUNOMODULATORY COMPOSITIONS, THEIR METHODS OF PREPARATION AND USE
PL376950A1 (pl) Immunogenna kompozycja
AU2003303513A8 (en) Tissue reactive compounds and compositions and uses thereof
AU2003228445A8 (en) Tissue composites and uses thereof
GB0222091D0 (en) Dental compositions and methods
IL163868A (en) Hemiasterlin derivatives and pharmaceutical compositions comprising them
AU2003254677A8 (en) Innervated artificial tissues and uses thereof
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
AU2003296369A1 (en) Imminoamines and preparation thereof
PL376790A1 (pl) Pochodne 3-fenylopirydoindolonu, sposób ich wytwarzania i ich zastosowanie terapeutyczne
AU2003213120A8 (en) Human rnase iii and compositions and uses thereof
GB0615918D0 (en) Composition and its therapeutic use
EP1620089A4 (en) Therapeutic and prophylactic compositions and their uses
AU2003271486A1 (en) Intraosseous dental implant and dental implant set
EP1583557A4 (en) VACCINE COMPOSITIONS AND METHODS
IL165612A0 (en) Novel arylimidazole derivatives preparation and therapeutic uses thereof
AU2003263895A8 (en) Contraceptive methods and formulations
SI1482967T1 (sl) Farmacevtski in kozmetični sestavki, ki vsebujejo PLGF-1
GB0207224D0 (en) Tenascin-W compositions and uses thereof
GB0327050D0 (en) Therapeutic methods compositions and uses
GB0317376D0 (en) Immunogenic protein and uses thereof
GB2394659B (en) Therapeutic and prophylactic preparations
GB0205826D0 (en) Therapeutic compositions and methods
GB0223915D0 (en) Benzofuran derivatives formulations and uses thereof